High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites

Documenti analoghi

• Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations
  di: Kersten, M J, et al.
  Pubblicazione: (2014)
• Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice
  di: Visco, Carlo, et al.
  Pubblicazione: (2020)
• The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells
  di: van Keimpema, Martine, et al.
  Pubblicazione: (2017)
• CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma
  di: Trøen, Gunhild, et al.
  Pubblicazione: (2013)
• MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis
  di: Vermaat, Joost S., et al.
  Pubblicazione: (2020)